Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 27, 2026Journal of Clinical MedicineOpen Access

Comparative Real-World Outcomes of OnabotulinumtoxinA and CGRP Monoclonal Antibodies in Chronic Migraine

View Full Paper
Ask AI
Bookmark
Share

Authors

CLC Koo Seen LinCCChen‐Chih ChungJCJia‐Hung Chen

Discussion

Loading...

Member takes

Overview

Retrospective cohort study compares acute triptan prescriptions and return visits for chronic migraine patients receiving two treatments, suggesting distinct healthcare utilization patterns.

Key Points

  • This study aims to compare the effects of onabotulinumtoxinA and CGRP monoclonal antibodies on healthcare utilization in chronic migraine patients.
  • Conducted a retrospective cohort study using TriNetX electronic health record database from 2018 to 2024.
  • Matched adults with chronic migraine initiating onabotulinumtoxinA or CGRP monoclonal antibody by propensity score (1:1).
  • Assessed primary outcomes of time to acute triptan prescription and time to first migraine-related return visit during follow-up.
  • OnabotulinumtoxinA showed a lower hazard of acute triptan prescription compared to CGRP monoclonal antibodies (HR 0.513, 95% CI 0.481–0.546; p<0.001).
  • Migraine-related return visits were similar between groups (HR 1.008, 95% CI 0.977–1.039; p=0.69).

Cite This Study

Lin et al. (2026) studied this question.

synapsesocial.com/papers/6a3f6843aea7db3c1953f6c9https://doi.org/10.3390/jcm15134963
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative effectiveness and tolerability of calcitonin gene‐related peptide ( CGRP) monoclonal antibodies and onabotulinumtoxinA in chronic migraine: A multicenter, real‐world study in Taiwan2024 · 11 citations
  2. 2Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program2026 · 1 citations
  3. 3Real-world effectiveness of onabotulinumtoxinA as first-line treatment in chronic migraine and sequential transition to anti-CGRP monoclonal antibodies: a retrospective multicenter study2026
  4. 4Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis2026
  5. 5Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review2024 · 12 citations